Drug intelligence / Profile preview

N3-[3-(1H-indol-6-yl)benzyl]pyridine-2,3-diamine

Development stage: Unknown
Modality: Small Molecules

Overview

N3-[3-(1H-indol-6-yl)benzyl]pyridine-2,3-diamine is an experimental small molecule compound containing an indole moiety and a pyridine diamine core. It has been identified as a β-secretase 1 (BACE1) inhibitor in chemical biology databases. BACE1 inhibitors are being investigated for their potential to reduce amyloid-beta production in Alzheimer's disease by blocking the cleavage of amyloid precursor protein (APP). There is no evidence of clinical development or approved therapeutic use for this compound at present[1][2][10].

Other names: N3-[3-(1H-Indol-6-yl)benzyl]-2,3-pyridinediamineN3-{[3-(1H-indol-6-yl)phenyl]methyl}pyridine-2,3-diamine

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on N3-[3-(1H-indol-6-yl)benzyl]pyridine-2,3-diamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N3-[3-(1H-indol-6-yl)benzyl]pyridine-2,3-diamine.

Explore the full profile